Summary
AbbVie Inc. reported strong financial results for the first quarter of 2016, with net revenues reaching $5.96 billion, an increase of 18% (22% on a constant currency basis) compared to the same period last year. This growth was primarily driven by the robust performance of its key products, HUMIRA and the recently acquired IMBRUVICA, along with contributions from VIEKIRA and other growth brands. Diluted earnings per share stood at $0.83, reflecting both operational strength and the impact of certain one-time items, including a significant foreign exchange loss related to Venezuela. The company demonstrated effective cost management, with selling, general, and administrative expenses as a percentage of net revenue decreasing due to strong revenue leverage, even as R&D investments continued to support a robust pipeline. AbbVie also generated substantial operating cash flow of $2.1 billion, enabling the company to return capital to shareholders through dividends and share repurchases, and to strategically invest in future growth. Significant post-quarter acquisitions and agreements, including the acquisition of Stemcentrx and a collaboration with Boehringer Ingelheim, highlight AbbVie's commitment to expanding its pipeline and therapeutic offerings, particularly in oncology.
Financial Highlights
52 data points| Revenue | $5.96B |
| Cost of Revenue | $1.37B |
| Gross Profit | $4.59B |
| SG&A Expenses | $1.35B |
| Operating Expenses | $3.68B |
| Operating Income | $2.28B |
| Interest Expense | $215.00M |
| Net Income | $1.35B |
| EPS (Basic) | $0.83 |
| EPS (Diluted) | $0.83 |
| Shares Outstanding (Basic) | 1.62B |
| Shares Outstanding (Diluted) | 1.63B |
Key Highlights
- 1Net revenues increased by 18% (22% constant currency) to $5.96 billion, driven by strong performance in HUMIRA and IMBRUVICA.
- 2Diluted earnings per share (EPS) were $0.83, demonstrating solid profitability despite a significant $298 million foreign exchange loss related to Venezuela.
- 3Operating cash flow was robust at $2.1 billion, supporting dividend payments ($924 million) and share repurchases ($300 million settled).
- 4Gross margin as a percentage of net revenue decreased to 77% from 81% due to higher amortization expense from the Pharmacyclics acquisition and inventory step-up.
- 5Selling, General & Administrative (SG&A) expenses as a percentage of net revenue decreased to 23% from 29%, reflecting strong revenue leverage.
- 6Research and Development (R&D) expenses increased 17% to $946 million, reflecting continued investment in the pipeline and post-acquisition R&D from Pharmacyclics.
- 7Subsequent to the quarter, AbbVie announced significant strategic moves, including the acquisition of Stemcentrx for approximately $5.8 billion and a collaboration with Boehringer Ingelheim for risankizumab, signaling a strong focus on pipeline expansion, particularly in oncology.